Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%

Reuters04-11 04:45

Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%

Corcept presented complete overall survival results from Phase 3 ROSELLA trial at SGO 2026, with simultaneous publication in The Lancet.
Study showed Lifyorli (relacorilant) with nab-paclitaxel extended survival versus nab-paclitaxel alone in platinum-resistant ovarian cancer.
Regimen was added to NCCN Guidelines as a preferred option for platinum-resistant ovarian cancer.
FDA cleared Lifyorli in March 2026 for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer following 1-3 prior systemic regimens.
Trial results supported use without a meaningful increase in overall treatment burden versus chemotherapy alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202604101645BIZWIRE_USPR_____20260410_BW882270) on April 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626487031?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-11 04:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626487031","market":"us","top_or_hot":-1,"title":"Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Corcept presented complete overall survival results from Phase 3 ROSELLA trial at SGO 2026, with simultaneous publication in The Lancet.\n        </li>\n<li>\n          Study showed Lifyorli (relacorilant) with nab-paclitaxel extended survival versus nab-paclitaxel alone in platinum-resistant ovarian cancer.\n        </li>\n<li>\n          Regimen was added to NCCN Guidelines as a preferred option for platinum-resistant ovarian cancer.\n        </li>\n<li>\n          FDA cleared Lifyorli in March 2026 for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer following 1-3 prior systemic regimens.\n        </li>\n<li>\n          Trial results supported use without a meaningful increase in overall treatment burden versus chemotherapy alone.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202604101645BIZWIRE_USPR_____20260410_BW882270) on April 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-11 04:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Corcept presented complete overall survival results from Phase 3 ROSELLA trial at SGO 2026, with simultaneous publication in The Lancet.\n        </li>\n<li>\n          Study showed Lifyorli (relacorilant) with nab-paclitaxel extended survival versus nab-paclitaxel alone in platinum-resistant ovarian cancer.\n        </li>\n<li>\n          Regimen was added to NCCN Guidelines as a preferred option for platinum-resistant ovarian cancer.\n        </li>\n<li>\n          FDA cleared Lifyorli in March 2026 for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer following 1-3 prior systemic regimens.\n        </li>\n<li>\n          Trial results supported use without a meaningful increase in overall treatment burden versus chemotherapy alone.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202604101645BIZWIRE_USPR_____20260410_BW882270) on April 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1559883803.SGD","symbol_name":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9jqNHm:1","article_id":"2626487031","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626487031","pubTimestamp":1775853920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Corcept presented complete overall survival results from Phase 3 ROSELLA trial at SGO 2026, with simultaneous publication in The Lancet.Study showed Lifyorli  with nab-paclitaxel extended survival versus nab-paclitaxel alone in platinum-resistant ovarian cancer.Regimen was added to NCCN Guidelines as a preferred option for platinum-resistant ovarian cancer.FDA cleared Lifyorli in March 2026 for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer following 1-3 prior systemic regimens.Trial results supported use without a meaningful increase in overall treatment burden versus chemotherapy alone.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","CORT":"Corcept医疗","BK4007":"制药","LU0566484027.USD":"安本美国小盘成长股","BK4532":"文艺复兴科技持仓"},"translate_title":"Corcept ROSELLA试验显示Lifyorli加白蛋白结合型紫杉醇可将死亡风险降低35%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":0.9},"content_text":"Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%\n    \n\n\n          Corcept presented complete overall survival results from Phase 3 ROSELLA trial at SGO 2026, with simultaneous publication in The Lancet.\n        \n\n          Study showed Lifyorli (relacorilant) with nab-paclitaxel extended survival versus nab-paclitaxel alone in platinum-resistant ovarian cancer.\n        \n\n          Regimen was added to NCCN Guidelines as a preferred option for platinum-resistant ovarian cancer.\n        \n\n          FDA cleared Lifyorli in March 2026 for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer following 1-3 prior systemic regimens.\n        \n\n          Trial results supported use without a meaningful increase in overall treatment burden versus chemotherapy alone.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202604101645BIZWIRE_USPR_____20260410_BW882270) on April 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626487031","isCrawlerRequest":true}